Eli Lilly & Co. mentioned its weight-loss drug Zepbound outperformed rival Novo Nordisk A/S’s Wegovy within the first head-to-head trial of the 2 blockbusters. Within the examine sponsored by Lilly, these on Zepbound misplaced a median of about 50 kilos over 72 weeks. Dr. Daniel Skovronsky, Eli Lilly chief scientific officer, spoke in regards to the outcomes on “Bloomberg Open Curiosity.”
——–
Extra on Bloomberg Tv and Markets
Like this video? Subscribe and activate notifications so you do not miss any movies from Bloomberg Markets & Finance: https://tinyurl.com/ysu5b8a9
Go to http://www.bloomberg.com for enterprise information & evaluation, up-to-the-minute market knowledge, options, profiles and extra.
Join with Bloomberg Tv on:
X: https://twitter.com/BloombergTV
Fb: https://www.fb.com/BloombergTelevision
Instagram: https://www.instagram.com/bloombergtv/
Join with Bloomberg Enterprise on:
X: https://twitter.com/enterprise
Fb: https://www.fb.com/bloombergbusiness
Instagram: https://www.instagram.com/bloombergbusiness/
TikTok: https://www.tiktok.com/@bloombergbusiness?lang=en
Reddit: https://www.reddit.com/r/bloomberg/
LinkedIn: https://www.linkedin.com/firm/bloomberg-news/
Extra from Bloomberg:
Bloomberg Radio: https://twitter.com/BloombergRadio
Bloomberg Surveillance: https://twitter.com/bsurveillance
Bloomberg Politics: https://twitter.com/bpolitics
Bloomberg Originals: https://twitter.com/bbgoriginals
Watch extra on YouTube:
Bloomberg Expertise: https://www.youtube.com/@BloombergTechnology
Bloomberg Originals: https://www.youtube.com/@enterprise
Bloomberg Quicktake: https://www.youtube.com/@BloombergQuicktake
Bloomberg Espanol: https://www.youtube.com/@bloomberg_espanol
Bloomberg Podcasts: https://www.youtube.com/@BloombergPodcasts
